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During late 2010, a previously unrecognised strain 
of measles genotype G3 virus was identified in five 
different European countries by the World Health 
Organization Measles and Rubella Laboratory Network. 
Apart from one, none had a travel history to south-east 
Asia, the usual source of G3 viruses, although epide-
miological links could be established between some 
of the cases. This case series illustrates the value of 
genotyping and sequencing in tracking measles infec-
tions, and identifying otherwise unrecognised chains 
of transmission.
Measles and Rubella Laboratory 
Network (LabNet)
As Europe adopts its resolution to eliminate measles by 
2015 [1] confirmation of clinically diagnosed measles, 
and characterisation of circulating viruses becomes 
increasingly pertinent. The World Health Organization 
(WHO) Measles and Rubella Laboratory Network 
(LabNet), was established in 2002, with the primary 
purpose of providing laboratory confirmation of sus-
pected cases of measles and rubella using standard-
ised ELISA-based IgM detection in serum or oral fluid. 
As of July 2010, the LabNet consists of 690 laboratories 
in 183 countries, all of which follow a standardised set 
of testing protocols and reporting procedures with a 
strong focus on quality assurance. The LabNet is struc-
tured in four tiers of laboratories: sub national (n=507), 
national level (n=161), regional reference (n=19), and 
global specialised (n=3). 
The LabNet also supports genetic characterisation of 
currently circulating strains of measles viruses and is 
responsible for standardisation of the nomenclature 
and laboratory procedures that are used for genetic 
characterisation of wild-type measles and rubella 
viruses [2-4].
This agreement of a standard nomenclature and clas-
sification for describing measles virus has been instru-
mental in allowing comparison of viruses in different 
countries, and also for documenting spread within 
countries, monitoring viral transmission pathways and 
in providing evidence of progress towards measles 
elimination [5].
For molecular epidemiologic purposes, the WHO cur-
rently recognises eight clades (designated A to H), and 
within these clades, there are 23 recognised geno-
types, designated A, B1, B2, B3, C1, C2, D1, D2, D3, 
D4, D5, D6, D7, D8, D9, D10, E, F, G1, G2, G3, H1, and 
H2. There is considerable genetic variability within 
some genotypes (e.g. B3 and H1) and related viruses 
are referred to as clusters. The WHO recommends that 
the 450 nucleotides coding for the carboxyterminal 150 
amino acids of the nucleoprotein (N-450) are the mini-
mum amount of sequence data required for assigning 
a measles genotype [2-4]. A WHO Measles nucleotide 
sequence database MeaNS ([6], www.who-measles.
org) was set up as a repository for sequence informa-
tion, with tools to allow genotyping and phylogenetic 
analysis of measles viruses sequences found globally.
Genotyping and sequencing of measles viruses is rec-
ommended by the WHO for at least 80% of all labora-
tory-confirmed outbreaks [7] and in countries where 
measles is no longer endemic, is encouraged for all 
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sporadic cases. Molecular characterisation of such 
cases provides the information necessary to determine 
whether they are part of a single cluster or due to mul-
tiple importations, and to identify sources of infection. 
However, unless appropriate samples are collected 
(generally throat swab, urine sample, or increasingly 
common in Europe, an oral fluid sample) genotype 
information is not always available. In the past three 
years, six different genotypes of measles virus have 
been identified in Europe (B3, D4, D5, D8, D9, H1) with 
large outbreaks associated with B3, D4 and D5 in many 
countries [8].
Recent infections with measles 
virus G3 in Europe
Measles genotype G3 is generally associated with 
measles infections in south-east Asia, or in sporadic 
cases with links to south-east Asia [4]. There had 
been no reported cases of measles G3 in Europe since 
2006. However, in the last four months of 2010 there 
have been a total of 25 sporadic (i.e. epidemiologically 
unlinked) or epidemiologically linked cases, all with 
viruses with identical sequence belonging to genotype 
G3, in several different countries in Europe.
The first case, Patient A was a non-vaccinated German 
adult who was on a roundtrip from Germany to south-
east Asia, during the first half of September 2010, and 
returned to Germany via London on 17 September 2010. 
Patient A remembered that a passenger sitting one row 
in front of them had influenza-like symptoms and was 
coughing frequently, but otherwise had no known con-
tact with potential infectious measles virus carriers. 
Ten days later Patient A felt ill, developed a rash after 
two more days and was hospitalised. Measles was con-
firmed by detection of measles virus RNA in oral fluid 
and urine sample [9].  
During the same period of symptom onset for Patient A, 
cases of measles were also detected in Spain, England 
and France (Figure 1).
The Spanish case (Patient B) returned to Spain on 20 
September 2010 after having travelled to London. Like 
Patient A, Patient B developed the prodrome on 27 
September, with rash onset on 3 October. These dates 
indicate a potential infection of both cases in London 
around 17 September.  
The third case was a college student in London (Patient 
C) with no history of travel outside the United Kingdom 
(UK), who became unwell on 28 September and who 
had rash onset on 2 October. Patient C subsequently 
infected two students at the same college in London 
(Patient D, onset date 12 October, and Patient E, onset 
date 14 October). Patient D had travelled to Switzerland 
and became unwell and was diagnosed with measles 
there. Subsequently there were two further cases of 
measles G3 virus infection, a household contact of 
Patient D (Patient F, onset date 27 October) and another 
case (Patient G, onset date 29 October) with no identi-
fied links, but living in the same town. 
Figure 1






















































The different styles of the outlines indicate the different countries where the cases were at the time of infection.
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A fourth patient in the UK (Patient H) also developed 
measles with a G3 genotype at the beginning of 
October 2010. Patient H had spent holidays in North 
Africa and returned to the UK on 20 September. The 
prodrome began on 1 October with rash onset four 
days later, suggesting infection at the time of travel 
or shortly after, and although this case did not live in 
London, they had travelled through London on the way 
home. Subsequently, over the next two months there 
were four further sporadic G3 measles cases, all with 
no history of travel outside south-east England. There 
were no further cases in the UK for the rest of 2010.
The French patient (Patient I) was a one year-old non-
vaccinated infant who lived in the area of Paris, and 
developed rash on 29 September. Like Patient C, there 
was no history of recent travel or known epidemiologi-
cal link to anyone with measles. On 16 October there 
was a second G3 measles confirmed case in France 
(Patient J), although no links between the two cases 
could be determined. Subsequently, there were a 
further nine sporadic cases of G3 measles identified in 
France up to the end of 2010, but given the widespread 
measles activity in France [10] links between these 
cases have been difficult to identify. 
Lastly, a visitor from Canada with a history of one dose 
of measles-containing vaccine as an infant, (Patient K) 
travelled to London on 10 September and then spent 
holidays in London, Paris and Amsterdam. Patient K 
also developed measles with a G3 genotype, with onset 
of rash on 4 October, suggesting infection around 20 
September before having returned to Canada.
Sequence analysis
Genotyping and sequencing was performed, by the 
respective national laboratory on a variety of samples 
from these patients. Sequencing of the recommended 
minimum 450 nucleotides [3] was performed and con-
firmed that they were all G3 sequences. Comparison of 
the sequences confirmed that all the samples, includ-
ing the one from the German patient with travel links 
Figure 2
Phylogenetic tree of representative sequences from the recent G3 measles cases, compared with other historic G3 measles 
cases, 2010
Numbers represent the ID number in the World Health Organization MeaNS database. 
The tree was created using the number of nucleotide differences to generate a distance matrix and the neighbour-joining algorithm to cluster 
sequences, as implemented within MEGA5. 








































to south-east Asia, were 100% identical over the N-450 
nucleotide sequence window (Figure 2).
 
Interestingly, there were no other identical sequences 
in the WHO MeaNS database or GenBank. Two viruses 
with similar sequences (five nucleotides difference) 
had previously been identified in cases in Singapore in 
early 2010 and had links to Indonesia.
The cluster described in this paper highlights a number 
of important points. Not only is it essential to have an 
agreed standard nomenclature for describing viruses, 
both at genotype and at sequence level, but it is also 
critical that this information is shared. Within the WHO 
laboratory network of national, regional and global 
laboratories, genotype information is shared by regular 
reporting to the WHO Regional Offices of the sequenc-
ing results, and depositing sequence information in the 
WHO MeaNS database or GenBank. The MeaNS data-
base is not only a repository for all reported measles 
sequences, but it also allows ready identification of 
identical or similar sequences in different countries, as 
in this case series. All laboratories performing measles 
genotyping and sequencing should be encouraged to 
submit their sequences in a timely manner to facilitate 
identification.
The cases described here also highlight how quickly 
measles viruses can spread, and become widely dis-
seminated. Judging by the estimated dates of infection, 
it could be hypothesised that the person travelling on 
the plane with Patient A was in the early stages of 
measles, and transmitted infection to the German co-
passenger and then to other cases in London, but that 
does not explain the index case in France. It is more 
likely that there were at least two independent impor-
tations of this G3 genotype to Europe (to France and the 
UK), and some early G3 infections have been missed. 
Almost certainly, the pocket of G3 measles infection 
in France has continued, with ongoing identification 
of G3 measles cases in France, as well as three further 
cases of G3 measles in the UK and two cases in Russia 
in February and March 2011, all with epidemiological 
links to infection in France. Similar small clusters of 
G3 measles cases have also recently been reported in 
Germany and the West Indies island of Saint Martin.
Conclusions
The number of identified G3 measles cases underesti-
mates the true level of G3 measles activity in Europe, 
because not all infected individuals seek medical 
advice, and because in most countries samples suit-
able for genotyping are not routinely collected from 
all cases and therefore sequence information is not 
available. Routine collection of oral fluid from all cases 
with clinically suspected measles does allow confirma-
tion of infection by serological or molecular methods 
and offers the potential for widespread genotyping to 
identify sources of importations and tracking of infec-
tion. Genotyping and molecular characterisation of cir-
culating measles viruses are of increasing importance 
in confirming the absence of endemic infection in each 
country as Europe aims for the elimination of measles 
by 2015 [1]. 
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